Short Interest in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Expands By 24.4%


Share on StockTwits

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 2,750,000 shares, an increase of 24.4% from the March 31st total of 2,210,000 shares. Approximately 2.7% of the shares of the stock are sold short. Based on an average daily volume of 996,300 shares, the days-to-cover ratio is currently 2.8 days.

REGN traded down $3.44 on Tuesday, reaching $485.18. The company’s stock had a trading volume of 745,603 shares, compared to its average volume of 977,554. The company has a market capitalization of $51.98 billion, a price-to-earnings ratio of 17.73, a P/E/G ratio of 0.82 and a beta of 0.30. Regeneron Pharmaceuticals has a fifty-two week low of $441.00 and a fifty-two week high of $664.64. The company has a quick ratio of 3.12, a current ratio of 3.89 and a debt-to-equity ratio of 0.27. The stock has a 50 day moving average of $482.38 and a two-hundred day moving average of $503.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, February 4th. The biopharmaceutical company reported $9.53 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $7.11 by $2.42. The company had revenue of $2.42 billion for the quarter, compared to analyst estimates of $2.40 billion. Regeneron Pharmaceuticals had a net margin of 38.28% and a return on equity of 28.97%. The firm’s revenue was up 11.7% on a year-over-year basis. During the same period in the prior year, the firm posted $7.50 earnings per share. As a group, analysts anticipate that Regeneron Pharmaceuticals will post 27.23 earnings per share for the current fiscal year.

REGN has been the subject of several recent research reports. Canaccord Genuity reaffirmed a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 13th. Morgan Stanley cut their price target on Regeneron Pharmaceuticals from $525.00 to $477.00 and set an “equal weight” rating for the company in a report on Monday, April 26th. BMO Capital Markets raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $630.00 price target for the company in a report on Monday, January 25th. SVB Leerink increased their price target on Regeneron Pharmaceuticals from $655.00 to $657.00 and gave the company an “outperform” rating in a report on Thursday, April 1st. Finally, Cantor Fitzgerald cut their price target on Regeneron Pharmaceuticals from $696.00 to $656.00 and set an “overweight” rating for the company in a report on Tuesday, February 16th. Five investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $644.17.

Hedge funds have recently bought and sold shares of the company. Exchange Traded Concepts LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 146.4% in the fourth quarter. Exchange Traded Concepts LLC now owns 3,943 shares of the biopharmaceutical company’s stock valued at $1,905,000 after acquiring an additional 2,343 shares during the period. Jacobs & Co. CA lifted its holdings in shares of Regeneron Pharmaceuticals by 10.8% during the first quarter. Jacobs & Co. CA now owns 12,035 shares of the biopharmaceutical company’s stock worth $5,694,000 after purchasing an additional 1,177 shares during the period. NN Investment Partners Holdings N.V. lifted its holdings in shares of Regeneron Pharmaceuticals by 407.3% during the fourth quarter. NN Investment Partners Holdings N.V. now owns 69,006 shares of the biopharmaceutical company’s stock worth $33,338,000 after purchasing an additional 55,403 shares during the period. Oak Associates Ltd. OH lifted its holdings in shares of Regeneron Pharmaceuticals by 6.5% during the fourth quarter. Oak Associates Ltd. OH now owns 3,195 shares of the biopharmaceutical company’s stock worth $1,544,000 after purchasing an additional 195 shares during the period. Finally, Vident Investment Advisory LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 17.2% during the fourth quarter. Vident Investment Advisory LLC now owns 9,674 shares of the biopharmaceutical company’s stock worth $4,672,000 after purchasing an additional 1,419 shares during the period. 85.00% of the stock is owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Story: How is the discount rate different from the Federal Funds rate?

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.